RNAC
NASDAQ · Biotechnology
Cartesian Therapeutics Inc
$6.49
+0.21 (+3.34%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 132.58M | 132.93M | 135.85M |
| Net Income | 3.35M | 3.48M | 3.56M |
| EPS | — | — | — |
| Profit Margin | 2.5% | 2.6% | 2.6% |
| Rev Growth | +18.2% | -1.8% | +9.5% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 72.40M | 76.99M | 61.16M |
| Total Equity | 92.50M | 89.31M | 77.96M |
| D/E Ratio | 0.78 | 0.86 | 0.78 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 5.30M | 5.52M | 5.23M |
| Free Cash Flow | 2.64M | 2.68M | 1.65M |